Autoantibodies to selenoprotein P in chronic fatigue syndrome suggest selenium transport impairment and acquired resistance to thyroid hormone

Sun, Qian; Oltra, Elisa; Dijck-Brouwer, D.A. Janneke; Chillon, Thilo Samson; Seemann, Petra; Asaad, Sabrina; Demircan, Kamil; Espejo-Oltra, José Andrés; Sánchez-Fito, Teresa; Martín-Martínez, Eva; Minich, Waldemar B.; Muskiet, Frits A. J.; Schomburg, Lutz

doi:10.1016/j.redox.2023.102796

Cited by 13 publications

(3 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…What is interesting, autoantibodies to the transporter of selenium (SELENOP) have been detected recently. The mentioned antibodies were shown to be present and to impair both the expression of selenoproteins together with the deiodination of thyroid hormones [59]. These new findings require a further elucidation to define the suitability of the antibodies against the SELENOP for diagnostic and therapeutic purposes.…”

Section: Seleniummentioning

confidence: 93%

Autoimmunity, New Potential Biomarkers and the Thyroid Gland—The Perspective of Hashimoto’s Thyroiditis and Its Treatment

Tywanek,

Michalak,

Świrska

et al. 2024

IJMS

View full text Add to dashboard Cite

Autoimmune thyroid disease (AITD) is the most common organic specific illness of the thyroid gland. It may manifest as the overproduction or the decline of thyroxine and triiodothyronine. Hyperthyroidism develops due to the overproduction of hormones as an answer to the presence of stimulatory antibodies against the TSH receptor. Hashimoto’s thyroiditis (HT) is generally characterized by the presence of thyroid peroxidase and thyroglobulin antibodies, with a concomitant infiltration of lymphocytes in the thyroid. Due to the progressive destruction of cells, AITD can lead to subclinical or overt hypothyroidism. Pathophysiology of AITD is extremely complicated and still not fully understood, with genetic, environmental and epigenetic factors involved in its development. Due to increasing incidence and social awareness of this pathology, there is an urgent need to expand the background concerning AITD. A growing body of evidence suggests possible ways of treatment apart from traditional approaches. Simultaneously, the role of potential new biomarkers in the diagnosis and monitoring of AITD has been highlighted recently, too. Therefore, we decided to review therapeutic trends in the course of AITD based on its pathophysiological mechanisms, mainly focusing on HT. Another aim was to summarize the state of knowledge regarding the role of new biomarkers in this condition.

show abstract

Section: Seleniummentioning

confidence: 93%

Autoimmunity, New Potential Biomarkers and the Thyroid Gland—The Perspective of Hashimoto’s Thyroiditis and Its Treatment

Tywanek,

Michalak,

Świrska

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…Additionally, a subgroup of hypothyroidic ME/CFS patients have recently been identified with autoimmunity to the selenium transporter SELENOP [240]. A combined administration of selenium and triiodothyronine (T3) has been proposed as a potential treatment for this subset of patients and provides a potential therapeutic opportunity for future CTs.…”

Section: Future Directionsmentioning

confidence: 99%

Advancing Research and Treatment: An Overview of Clinical Trials in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Future Perspectives

Seton,

Espejo-Oltra,

Giménez-Orenga

et al. 2024

JCM

View full text Add to dashboard Cite

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic, debilitating, and multi-faceted illness. Heterogenous onset and clinical presentation with additional comorbidities make it difficult to diagnose, characterize, and successfully treat. Current treatment guidelines focus on symptom management, but with no clear target or causative mechanism, remission rates are low, and fewer than 5% of patients return to their pre-morbid activity levels. Therefore, there is an urgent need to undertake robust clinical trials to identify effective treatments. This review synthesizes insights from clinical trials exploring pharmacological interventions and dietary supplements targeting immunological, metabolic, gastrointestinal, neurological, and neuroendocrine dysfunction in ME/CFS patients which require further exploration. Additionally, the trialling of alternative interventions in ME/CFS based on reported efficacy in the treatment of illnesses with overlapping symptomology is also discussed. Finally, we provide important considerations and make recommendations, focusing on outcome measures, to ensure the execution of future high-quality clinical trials to establish clinical efficacy of evidence-based interventions that are needed for adoption in clinical practice.

show abstract

“…After one year of supplementation with selenium, fatigue scores decreased in patients with solid tumors and hematological cancer [50]. In a recent trial, selenium biomarkers, such as plasma selenium, glutathione peroxidase, and selenoprotein P, showed linear correlations in patients with chronic fatigue syndrome without reaching saturation, indicative of Se deficiency [51].…”

Section: Effect Of Rehabilitation and Selenium Supplementation On Key...mentioning

confidence: 99%

Selenium in Cancer Rehabilitation—A Retrospective Study from a Specialized Clinic

Pfister,

Schoenemann

2023

Nutrients

View full text Add to dashboard Cite

Background: Micronutrient deficiencies are common at the time of cancer diagnosis and are associated with worse prognosis. Little is known about them in cancer rehabilitation. Methods: Data from routine health-related quality of life (HRQOL) were analyzed at an inpatient cancer rehabilitation center. Rehabilitation patients completed the EORTC QLQ-C30 questionnaire before and after multidisciplinary rehabilitation treatment and three months after discharge. Selenium and zinc status were measured in whole blood at these three time points. In case of selenium deficiency, up to 600 µg selenium per day as sodium selenite was supplemented for three weeks during and for three months after rehabilitation. Results: A total of 271 patients (breast, colon, and pancreatic cancer) were included in the analysis. There was clinically meaningful improvement in many domains of the EORTC QLQ-C30 during rehabilitation. However, the effect often waned in the three months after. Prevalence for selenium deficiency varied between 34 to 90% depending on cancer type (breast < colon < pancreas). In contrast, zinc deficiency was rare. Daily selenium supplementation of 600 µg was more efficient to correct selenium deficiency compared to 300 µg selenium per day. Rehabilitation and increasing selenium status after rehabilitation were associated with improved global quality of life, physical and emotional functioning, and fatigue. In cancer patients with decreasing selenium status, values of global quality of life, physical and emotional functioning, and fatigue were back to the values at the beginning of rehabilitation. Conclusions: Selenium deficiency is common in cancer patients admitted to a cancer rehabilitation clinic. Selenium supplementation during rehabilitation effectively corrected selenium deficiency in most cases. The positive effects of rehabilitation persisted longer when selenium status did not decrease after rehabilitation.

show abstract

Autoantibodies to selenoprotein P in chronic fatigue syndrome suggest selenium transport impairment and acquired resistance to thyroid hormone

Cited by 13 publications

References 64 publications

Autoimmunity, New Potential Biomarkers and the Thyroid Gland—The Perspective of Hashimoto’s Thyroiditis and Its Treatment

Autoimmunity, New Potential Biomarkers and the Thyroid Gland—The Perspective of Hashimoto’s Thyroiditis and Its Treatment

Advancing Research and Treatment: An Overview of Clinical Trials in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Future Perspectives

Selenium in Cancer Rehabilitation—A Retrospective Study from a Specialized Clinic

Contact Info

Product

Resources

About